Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志
中国生物工程杂志  2020, Vol. 40 Issue (5): 1-6    DOI: 10.13523/j.cb.2003076
专稿     
新冠病毒抗体药物研发进展及展望分析
武瑞君,李治非,张鑫,濮润,敖翼(),孙燕荣()
中国生物技术发展中心 北京 100039
Development and Prospect of Antibody Drugs for SARS-CoV-2
WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi(),SUN Yan-rong()
China National Center for Biotechnology Development, Beijing 100039,China
 全文: PDF(732 KB)   HTML
摘要：

抗体药物以其独特的作用机制和靶向性强、特异性好等优点,在恶性肿瘤、自身免疫性疾病、感染类疾病的诊断和治疗中发挥着越来越重要的作用,成为国际创新药物研发的热点。新冠肺炎(COVID-19)疫情发生以来,国内外多家研究机构和企业正在加快推进新冠病毒(SARS-CoV-2)抗体药物的开发。在此情势下,认真分析抗体药物现状和趋势,梳理国内外新冠病毒抗体药物研究进展,明确我国当前抗体药物创新的机遇、挑战和建议,对加快我国药物自主创新研发具有重要意义。
关键词： 新冠病毒;  抗体药物;  药物研发;  新冠肺炎    
Abstract:

With their unique advantages of high affinity and high specificity, antibody drugs have played an increasingly important role in the diagnosis and treatment of malignant tumors, autoimmune diseases, and infectious diseases, becoming the focus of international innovative drug research. Since the outbreak of COVID-19, many research institutions and enterprises at home and abroad are in accelerated development of antibody drugs. In this situation, a systematic analysis of the status and trends of antibody drugs, the research progress of new antibody drugs for SARS-CoV-2, and the opportunities, challenges and suggestions for current antibody drug innovation in China is of great significance to promote the independent innovation of antibody drugs in China.
Key words: SARS-CoV-2    Antibody drugs    Drug research    Coronavirus disease 2019(COVID-19)
收稿日期: 2020-03-30 出版日期: 2020-06-02
ZTFLH:  Q78  
通讯作者: 敖翼,孙燕荣     E-mail: aoyi@cncbd.org.cn;sunry@cncbd.org.cn
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
武瑞君
李治非
张鑫
濮润
敖翼
孙燕荣

引用本文:

武瑞君,李治非,张鑫,濮润,敖翼,孙燕荣. 新冠病毒抗体药物研发进展及展望分析[J]. 中国生物工程杂志, 2020, 40(5): 1-6.

WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2. China Biotechnology, 2020, 40(5): 1-6.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2003076    或    https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I5/1

图1  抗体结构示意图(a)和单抗药物技术路线图(b)
图2  2010~2019年FDA批准新药数量和抗体药物数量汇总图[9]
[1] Perez H L, Cardarelli P M, Deshpande S , et al. Antibody-drug conjugates: current status and future directions. Drug Discovery Today, 2013, 10.1016/j.drudis.2013.11.004.
doi: 10.1016/j.drudis.2013.11.004
[2] Mould D R, Meibohm B . Drug Development of therapeutic monoclonal antibodies. BioDrugs, 2016,30:275-293.
[3] WHO. Coronavirus disease (COVID-19) outbreak.[2020-03-26]. https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd.
[4] 陶维红, 李宗海, 李荣秀 . 我国单克隆抗体药物产业化进展浅谈. 生物产业技术, 2019,02(3月):75-80.
Tao W H, Li Z H, Li R X . Progress of monoclonal antibody drug industrialization in China. Biobusiness, 2019,02(March):75-80.
[5] Kretschmer A, Schwanbeck R, Valerius T , et al. Antibody isotypes for tumor immunotherapy. Transfus Med Hemother, 2017,44(5):320-326.
doi: 10.1159/000479240
[6] Nimmerjahn F, Ravetch J V . Analyzing antibody-fc-receptor interactions. Methods in Molecular Biology, 2008,415:151-162.
[7] 陈秀秀, 吴成林, 周丽君 . 人源抗体制备及临床应用研究进展. 中国生物工程杂志, 2019,39(10):90-96.
Chen X X, Wu C L, Zhou L J . Research progress in preparation and clinical application of human antibodies. China Biotechnology, 2019,39(10):90-96.
[8] Emmons C, Hunsicker L G . Muromonab-CD3 (Orthoclone OKT3): The first monoclonal antibody approved for therapeutic use. Lowa Med, 1987,77:78-82.
[9] U.S. Food&Drug Administration Advancing health through innovation: New drug therapy approvals 2019. [2020.03.01]. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2019.
[10] 高倩, 江洪, 叶茂 , 等. 全球单克隆抗体药物研发现状及发展趋势[J]. 中国生物工程杂志, 2019,39(3):111-119.
Gao Q, Jiang H, Ye M , et al. Status and development trend of global monoclonal antibody drug. China Biotechnology, 2019,39(3):111-119.
[11] 李敏, 吴日伟 . 国内外单抗药物市场概述. 中国生物工程杂志, 2017,37(3):106-114.
Li M, Wu R W . Overview of the monoclonal antibody drug market at home and abroad. China Biotechnology, 2017,37(3):106-114.
[12] 中华人民共和国国家卫生健康委员会. 截至3月25日24时新型冠状病毒肺炎疫情最新情况.[2020-03-26]. http://www.nhc.gov.cn/xcs/yqtb/202003/f01fc26a8a7b48debe194bd1277fdba3.shtml.
National Health Commission of the People's Republic of China. The latest situation of COVID-19 (March 25 24:00). [2020-03-26]. http://www.nhc.gov.cn/xcs/yqtb/202003/f01fc26a8a7b48debe194bd1277fdba3.shtml.
[13] Yan R H, Zhang Y Y, Guo Y Y , et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. bioRxiv, doi: 10.1101/2020.02.19.956946.
doi: 10.1101/2020.02.19.956946
[14] Lan J, Ge J W, Yu J F , et al. Crystal structure of the 2019-nCoV spike receptor-binding domin bound with the ACE2 receptor. bioRxiv, doi: 10.1101/2020.02.19.956235.
doi: 10.1101/2020.02.19.956235
[15] Klasse P J, Sattentau Q J . Mechanisms of virus neutralization by antibody. Current Topics in Microbiology and Immunology, 2001,260:87-108.
[16] Ju B, Zhang Q, Ge X Y , et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv, doi: 10.1101/2020.03.21.990770.
doi: 10.1101/2020.03.21.990770
[17] Wang Q H, Zhang Y F, Wu L L , et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell, doi: 10.1016/j.cell.2020.03.045.
doi: 10.1016/j.cell.2020.03.045
[18] Oldfield V, Dhillon S, Plosker G L . Tocilizumab a review of its use in the management of rheumatoid arthritis. Drugs, 2009,69:609-632.
[19] 中华人民共和国国家卫生健康委员会. 关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知.[2020-03-04]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
National Health Commission of the People's Republic of China. Notice on issuing diagnosis and treatment plan for COVID-19 (Trial Version 7). [2020-03-04]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[20] Wang C Y, Li W T, Drabek D , et al. A human monoclonal I antibody blocking SARS-CoV-2 infection. bioRxiv, doi: 10.1101/2020.03.11.987958.
doi: 10.1101/2020.03.11.987958
[21] 周丽丽, 郑祝华 . 类风湿性关节炎治疗药——Kevzara. 药学研究, 2017, 36,(7):432-434.
Zhou L L, Zheng Z H . Rheumatoid arthritis drugs——Kevzara. Journal of Pharmaceutical Research, 2017,36:7.
[22] 中国临床试验注册中心. 评价依奇珠单抗联合临床常规抗病毒药物治疗新型冠状肺炎(COVID-19)患者的有效性和安全性的随机盲法对照多中心临床试验.[2020-03-10]. http://www.chictr.org.cn/showproj.aspx?proj=50251.
Chinese Clinical Trial Registry. A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19) .[2020-03-10]. http://www.chictr.org.cn/showproj.aspx?proj=50251.
[1] 贠涛,巩玥,谷芃,徐冰冰,李瑾,赵洗尘. 中国与“一带一路”参与国家抗击新冠肺炎疫情的国际科技合作现状与展望[J]. 中国生物工程杂志, 2021, 41(7): 110-121.
[2] 陈晨,胡劲超,曹姗姗,门冬. 新型冠状病毒抗原快速检测研发现状及展望*[J]. 中国生物工程杂志, 2021, 41(6): 119-128.
[3] 许叶春,柳红,李剑峰,沈敬山,蒋华良. 抗新冠肺炎药物研究进展[J]. 中国生物工程杂志, 2021, 41(6): 111-118.
[4] 史瑞,严景华. 抗新型冠状病毒单克隆中和抗体药物研发进展*[J]. 中国生物工程杂志, 2021, 41(6): 129-135.
[5] 傅桂娥,李瑾,耿佩然,申梦秋,张金倩楠,赵洗尘. 医疗视角下粤港澳大湾区典型城市的新冠肺炎(COVID-19)疫情防控力量比较研究*[J]. 中国生物工程杂志, 2021, 41(12): 125-140.
[6] 朱小丽,黄翠,马丽丽,张超,巩玥,赵婉雨,赵秀芳,郭文姣,彭皓,张吉,梁慧刚. 新型冠状病毒病(COVID-19)研究进展[J]. 中国生物工程杂志, 2020, 40(1-2): 38-50.
[7] 林福玉,刘金毅,程永庆. 重组人干扰素α1b抗新型冠状病毒的基础和临床研究进展[J]. 中国生物工程杂志, 2020, 40(12): 1-7.
[8] 吝建华,韩君,徐寒梅. PD-1/PD-L1免疫检查点抗体药物制剂稳定性开发[J]. 中国生物工程杂志, 2020, 40(10): 35-42.
[9] 谢志勇,周翔. 基于机器学习的医学影像分析在药物研发和精准医疗方面的应用[J]. 中国生物工程杂志, 2019, 39(2): 90-100.
[10] 刘国芳,刘晓志,高健,王志明. 宿主细胞残留蛋白质对单克隆抗体药物质量影响及其质量控制 *[J]. 中国生物工程杂志, 2019, 39(10): 105-110.
[11] 杜力,刘晓志,高健,王志明. 抗体药物免疫原性评估的研究进展[J]. 中国生物工程杂志, 2018, 38(2): 89-94.
[12] 黄怡,李晓宇,田芳,钱小红,应万涛. 质谱方法实现抗体类药物糖链修饰的鉴定与定量研究[J]. 中国生物工程杂志, 2018, 38(1): 32-41.
[13] 吴升星, 李艳, 张海燕, 刘洋, 赖琼, 杨明. 诱导多能干细胞技术在药物研发领域中的前景[J]. 中国生物工程杂志, 2017, 37(11): 116-122.
[14] 任华景, 刘晓志, 王志明, 高健. 中枢神经系统疾病治疗性抗体药物应用进展[J]. 中国生物工程杂志, 2016, 36(9): 54-58.
[15] 陈龙冠, 覃锦红, 黄云娜, 麦俊新, 谢秋玲. 信号肽优化对重组抗体分泌表达的影响及研究进展[J]. 中国生物工程杂志, 2016, 36(3): 77-81.
主管：中国科学院 　主办：中国科学院文献情报中心 　中国生物技术发展中心 　中国生物工程学会